Table 3. PJP prophylaxis
| Agent . | Dose . | Route . | Schedule . | Special notes . |
|---|---|---|---|---|
| Preferred | ||||
| TMP/SMX | 80/400 mg (SS)160/800 mg (DS) | Oral | If use SS give dailyIf use DS give 3 × week | Renally dose if renal dysfunctionMonitor for neutropenia and transaminase elevations |
| Alternatives | ||||
| Dapsone | 100 mg | Oral | Daily | Should not be given to patients with glucose-6-phosphate dehydrogenase deficiency |
| Atovaquone | 1500 mg | Oral | Daily | Take with fatty meal |
| Pentamidine | 300 mg | Inhaled/intravenous | Monthly |
| Agent . | Dose . | Route . | Schedule . | Special notes . |
|---|---|---|---|---|
| Preferred | ||||
| TMP/SMX | 80/400 mg (SS)160/800 mg (DS) | Oral | If use SS give dailyIf use DS give 3 × week | Renally dose if renal dysfunctionMonitor for neutropenia and transaminase elevations |
| Alternatives | ||||
| Dapsone | 100 mg | Oral | Daily | Should not be given to patients with glucose-6-phosphate dehydrogenase deficiency |
| Atovaquone | 1500 mg | Oral | Daily | Take with fatty meal |
| Pentamidine | 300 mg | Inhaled/intravenous | Monthly |
DS, double strength; SS, single strength.